A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP). It is a member of the larger family of PDE inhibitors .

Jun 8, 2022 · PDE-4: This type is specific to your lungs, causing muscles in your airway (especially your bronchial tubes) to constrict and tense up. PDE-5: These are in the lungs, and in the penis (for those assigned male sex at birth). Phosphodiesterase (PDE) inhibitors are medications that block those enzymes.

Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity.

Phosphodiesterase 4 (PDE4) inhibitors are a class of medications used to manage inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and psoriasis. These drugs work by reducing inflammation, which helps control symptoms and improve overall quality of life.

The aim of this review was to provide the reader with an overview of PDE4 targeting compounds that have reached clinical trials in the last ten years, since the first PDE4 inhibitor was marketed, with a focus on those most recently developed for respiratory, skin and neurological disorders.

Apr 20, 2020 · PDE4 inhibitors are a new type of treatment for plaque psoriasis that prevents inflammation. Here's what you need to know.

In this review, we provide an overview of the variety of PDE4 isoforms and how their activity and inhibition is influenced by post-translational modifications and interactions with partner proteins.

Phosphodiesterase4 inhibitors are currently under development for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease.

Introduction: Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis of cAMP, which has become an attractive therapeutic target for lung, skin, and severe neurological diseases. Here, we review the current status of development of PDE4 inhibitors since 2013 and discuss the applicability of novel medicinal-chemistry ...

Oct 17, 2018 · Over the past decades, numerous PDE4 inhibitors have been designed and synthesized, among which roflumilast, apremilast, and crisaborole were approved for the treatment of inflammatory airway diseases, psoriatic arthritis, and atopic dermatitis, respectively.